Panbela Therapeutics, Inc.
PBLADelisted Apr 25, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001029125
Panbela Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Nov 19, 2024; 11 institutions reported holding it in 13F filings for Q4 2023, worth $115.8K in total; no superinvestor held it.
13F holders, Q2 2022
Institutional positions in Panbela Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −3 vs. Q1 2022
- Shares held
- 171.4K
- −673.9K (−79.7%) vs. Q1 2022
- Total value
- $111.0K
- −$1.67M (−93.8%) vs. Q1 2022
- New holders
- 3
- 2 more added
- Sold out
- 6
- 1 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PBLA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 11 | $115.8K |
| Q3 2023 | 7 | $71.8K |
| Q2 2023 | 9 | $945.1K |
| Q1 2023 | 20 | $857.7K |
| Q4 2022 | 15 | $34.5K |
| Q3 2022 | 17 | $801.0K |
| Q2 2022 | 13 | $111.0K |
| Q1 2022 | 16 | $1.78M |
| Q4 2021 | 17 | $1.72M |
| Q3 2021 | 18 | $2.41M |
| Q2 2021 | 17 | $3.12M |
| Q1 2021 | 15 | $2.74M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Panbela Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Brand Asset Management Group, Inc. | 57,144 | $38.0K | 0.02% | 00.0% | Unchanged |
| Buckingham Strategic Wealth, LLC | 24,927 | $16.0K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 18,540 | $12.0K | 0.00% | +18,540 | New |
| Ergoteles LLC | 16,000 | $11.0K | 0.00% | +16,000 | New |
| Geode Capital Management, LLC | 13,958 | $9.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 12,500 | $8.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 12,831 | $8.00K | 0.00% | +11,459+835.2% | Added |
| Citadel Advisors LLC | 10,793 | $7.00K | 0.00% | +10,793 | New |
| Advisor Group Holdings, Inc. | 3,115 | $2.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 408 | $0 | 0.00% | −992−70.9% | Reduced |
| Royal Bank of Canada | 500 | $0 | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 633 | $0 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 78 | $0 | 0.00% | +6+8.3% | Added |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −355,959−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −228,401−100.0% | Sold out |
| Fieldpoint Private Securities, LLC | 0 | $0 | 0.00% | −62,621−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −34,018−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −28,723−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |